Huakang Biomedical Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Huakang Biomedical Holdings heeft een totaal eigen vermogen van CN¥56.5M en een totale schuld van CN¥2.9M, wat de schuld-eigenvermogensverhouding op 5.1% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥66.8M en CN¥10.3M.

Belangrijke informatie

5.1%

Verhouding schuld/eigen vermogen

CN¥2.88m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥36.66m
Aandelen	CN¥56.50m
Totaal verplichtingen	CN¥10.29m
Totaal activa	CN¥66.79m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥56.3M ) 8622 } overtreffen de korte termijn passiva ( CN¥9.7M ).

Langlopende schulden: De kortetermijnactiva 8622 ( CN¥56.3M ) overtreffen de langetermijnschulden ( CN¥611.0K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 8622 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 8622 is de afgelopen 5 jaar gestegen van 0% naar 5.1%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 8622 heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: 8622 heeft voldoende kasruimte voor meer dan 3 jaar als de vrije kasstroom blijft groeien met historische percentages van 23.8 % per jaar.

Huakang Biomedical Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven